A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-39439335 in Patients With Osteoarthritis

Inclusion Criteria: * Nonsmoker \>= 6 months prior to first dose * body mass index (BMI) \<= 36 kg/m2 * Meet American College of Rheumatology (ACR) clinical classification criteria for osteoarthritis of knee by meeting at least 3 of the following: age \> 50, morning stiffness \< 30 minutes, crepitus on active motion, bony tenderness, bony enlargement, no palpable warmth of synovium * Has Functional Class I-III osteoarthritis (OA) of knee with continuing OA-knee joint pain \>= 5 days/week x 3 months prior to screening, and has been taking a non-opioid analgesic for OA knee pain daily for \>=5 days prior to screening with benefit * Otherwise healthy based on physical exam, medical history, vital signs, 12-lead electrocardiogram (ECG), can clinical laboratory tests * Women must be postmenopausal or surgically sterile. Exclusion Criteria: * Oral temperature \>37.5 deg C at Screening or Day -1 * Failure of burn prevention measures quiz at Screening * patients with occupations or hobbies in which they are routinely exposed to situations in which they could sustain burns * orthopedic and/or prosthetic device on target knee joint * Significant pain outside the target knee, including significant hip or back pain (bilateral knee OA is permitted) * Unable to discontinue prior analgesic medications/non-steroidal antiinflammatory drugs (NSAIDS) other than paracetamol during the study * Surgical intervention for any pain within 3 months prior to screening or has plans for surgical intervention while in the study * History of prior diagnosis of inflammatory arthritis (including rheumatoid arthritis) * Treatment with local corticosteroid injections or viscosupplementation in target joint, or use of oral or intramuscular corticosteroids, within 3 months prior to Screening * History of active peptic ulceration, active dyspepsia, gastrointestinal bleeding, Crohn's disease, ulcerative colitis, chronic diarrhea esophageal, and gastric or duodenal ulcer within 3 months prior to screening or any other condition, which in the Investigator's opinion, precludes use of an NSAID.